Your browser doesn't support javascript.
loading
Monoclonal antibody therapeutics: history and future.
Buss, Nicholas A P S; Henderson, Simon J; McFarlane, Mary; Shenton, Jacintha M; de Haan, Lolke.
Affiliation
  • Buss NA; Biologics Safety Assessment, MedImmune, Granta Park, Cambridge CB21 6GH, UK. bussn@medimmune.com
Curr Opin Pharmacol ; 12(5): 615-22, 2012 Oct.
Article in En | MEDLINE | ID: mdl-22920732
Over the last three decades, monoclonal antibodies have made a dramatic transformation from scientific tools to powerful human therapeutics. At present, approximately 30 therapeutic monoclonal antibodies are marketed in the United States and Europe in a variety of indications, with sales in the US alone reaching approximately $18.5 billion in 2010. This review describes how antibody engineering has revolutionized drug discovery and what are considered the key areas for future development in the monoclonal antibody therapy field.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal Limits: Animals / Humans Language: En Journal: Curr Opin Pharmacol Journal subject: FARMACOLOGIA Year: 2012 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal Limits: Animals / Humans Language: En Journal: Curr Opin Pharmacol Journal subject: FARMACOLOGIA Year: 2012 Document type: Article Country of publication: United kingdom